| Kim, Jae Weon |
NCT04655482: Treat-and-extend Using Aflibercept for Type 3 Neovascularization |
|
|
| Recruiting | 4 | 30 | RoW | Aflibercept Injection, Intravitreal injection of aflibercept (Eylea, Bayer co.) | Kim's Eye Hospital, Bayer | Retinal Angiomatous Proliferation | 12/23 | 08/24 | | |
NCT04840550: Study to Evaluate the Safety, Efficacy of Tegoprazan for the Prevention of PUD in Patients on Treatment With NSAIDs |
|
|
| Recruiting | 3 | 390 | RoW | Lansoprazole 15 mg, Tegoprazan 25 mg | HK inno.N Corporation | Preventive Peptic Ulcer | 06/24 | 07/24 | | |
| Recruiting | 3 | 496 | RoW | Neu2000KWL group, Placebo group | GNT Pharma | Ischemic Stroke | 06/24 | 01/25 | | |
| Recruiting | 3 | 260 | Europe, Canada, Japan, RoW | Carboplatin-Paclitaxel, Dostarlimab | ARCAGY/ GINECO GROUP, GlaxoSmithKline | Endometrial Cancer | 04/26 | 10/29 | | |
| Recruiting | 2 | 100 | US, RoW | VGT-309 | Vergent Bioscience, Inc. | Lung Cancer, Lung Metastases | 11/24 | 12/24 | | |
EB-203-201, NCT06487039: Trial to Evaluate the Safety and Efficacy of EB-203 in Patients With Neovascular Age-related Macular Degeneration |
|
|
| Recruiting | 2 | 50 | RoW | EB-203 | EyebioKorea, Inc. | Neovascular Age-related Macular Degeneration (nAMD) | 08/25 | 01/26 | | |
NCT05933031: Exploratory Study to Standard Triple Therapy With Tegoprazan(by Dose) in H. Pylori Positive Patients |
|
|
| Recruiting | 2 | 381 | RoW | Tegoprazan 50 mg Triple Therapy, Tegoprazan 100 mg Triple Therapy, Lansoprazole Triple Therapy | HK inno.N Corporation | Helicobacter Pylori Infection | 12/24 | 12/24 | | |
NCT06116916: Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema |
|
|
| Recruiting | 2 | 150 | Japan, US, RoW | KHK4951, Aflibercept Injection | Kyowa Kirin Co., Ltd. | Diabetic Macular Edema (DME) | 11/25 | 12/25 | | |
NCT06116890: Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration |
|
|
| Recruiting | 2 | 180 | Japan, US, RoW | KHK4951, Aflibercept Injection | Kyowa Kirin Co., Ltd. | Neovascular Age-Related Macular Degeneration (nAMD) | 11/25 | 12/25 | | |
TANGO, NCT06029595: Efficacy and Safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund Maintenance Therapy |
|
|
| Recruiting | 2 | 464 | Europe, RoW | Experimental: CHF6001 3200 μg, Placebo Comparator: CHF6001 Placebo | Chiesi Farmaceutici S.p.A. | Uncontrolled Asthma | 12/25 | 12/25 | | |
NCT05509543: Study to Evaluate the Safety and the Pharmacokinetics of IY-NT-T |
|
|
| Completed | 1 | 60 | RoW | IY-NT-T, IY-NT-R, Noltec(the brand name) | Il-Yang Pharm. Co., Ltd. | Pharmacokinetics | 10/22 | 12/23 | | |
NCT05729386: A Study to Evaluate the Safety, PK of GC2129A in Healthy Volunteers Under Fed Conditions |
|
|
| Recruiting | 1 | 34 | RoW | GC2129A(Period 1), Linaglptin 5mg and Metformin Hydrocholoride 1000mg(Period 1), GC2129A(Period 2), Linaglptin 5mg and Metformin Hydrochloride 1000mg(Period 2) | GC Biopharma Corp | Healthy Volunteers | 04/23 | 04/23 | | |
NCT05703984: A Study to Evaluate the Safety, PK of GC2129A in Healthy Volunteers Under Fasting Conditions |
|
|
| Recruiting | 1 | 50 | RoW | GC2129A(Period 1), Linaglptin 5mg and Metformin Hydrocholoride 1000mg(Period 1), GC2129A(Period 2), Linaglptin 5mg and Metformin Hydrochloride 1000mg(Period 2) | GC Biopharma Corp | Healthy Volunteers | 04/23 | 04/23 | | |
NCT05617651: Study to Evaluate the Safety and the Pharmacokinetics of IY-NT-T |
|
|
| Not yet recruiting | 1 | 50 | RoW | IY-NT-T, IY-NT-R, Noltec(the brand name) | Il-Yang Pharm. Co., Ltd. | Pharmacokinetics | 12/24 | 12/25 | | |
NCT05525949: Visual Perceptual Learning Based Digital Therapeutics for Visual Field Defect After Stroke |
|
|
| Completed | N/A | 93 | RoW | VIVID Brain, No-treatment Control | Nunaps Inc | Visual Fields Hemianopsia, Hemianopsia, Homonymous | 08/23 | 11/23 | | |
NCT06406439: DIA:CONN P8(Smart Insulin Pen) Study in Diabetes Patients |
|
|
| Recruiting | N/A | 120 | RoW | Smart Insulin Pen, DIA:CONN P8 | G2e Co., Ltd | Diabetes Mellitus | 10/24 | 12/24 | | |
| Kim, ManSoo |
NCT04718649: Effectiveness and Safety of Celecoxib (Celebrex 200 mg) Combined With Joins in the Treatment of Degenerative Knee Osteoarthritis: a Randomized Controlled Trial |
|
|
| Not yet recruiting | N/A | 216 | RoW | Celebrex with Joins or not | The Catholic University of Korea, SK Chemicals Co., Ltd. | Osteoarthritis | 12/22 | 12/22 | | |
| In, Yong |
| Active, not recruiting | 3 | 104 | RoW | Autologous Chondrocyte Implantation (CartiLife®), CartiLife, Microfracture Surgery | Biosolution Co., Ltd. | Articular Cartilage Defect, Articular Cartilage Degeneration | 09/23 | 09/24 | | |
NCT04427930: Follow-up Study for Participants of Jointstem Phase 3 Clinical Trial |
|
|
| Active, not recruiting | 3 | 129 | RoW | JOINTSTEM | R-Bio | Knee Osteoarthritis | 12/26 | 12/27 | | |
NCT04718649: Effectiveness and Safety of Celecoxib (Celebrex 200 mg) Combined With Joins in the Treatment of Degenerative Knee Osteoarthritis: a Randomized Controlled Trial |
|
|
| Not yet recruiting | N/A | 216 | RoW | Celebrex with Joins or not | The Catholic University of Korea, SK Chemicals Co., Ltd. | Osteoarthritis | 12/22 | 12/22 | | |
| Park, Dong Ho |
| Recruiting | 3 | 612 | Europe, Canada, US, RoW | ABX464, Obefazimod, Placebo | Abivax S.A. | Ulcerative Colitis | 03/25 | 04/25 | | |
NCT06062030: Efficacy and Safety of DWJ1609 for Bowel Cleansing Before Colonoscopy; |
|
|
| Completed | 3 | 215 | RoW | DWJ1609, DWC202304, Orafang Tab | Daewoong Pharmaceutical Co. LTD. | Colonoscopy | 06/24 | 06/24 | | |
| Recruiting | 3 | 778 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Crohn's Disease | 11/24 | 12/26 | | |
| Recruiting | 3 | 1050 | Europe, Canada, Japan, US, RoW | ABX464, Obefazimod, Placebo | Abivax S.A. | Ulcerative Colitis | 01/26 | 01/30 | | |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
PLATINUM, NCT05338619: A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy |
|
|
| Recruiting | 2 | 77 | RoW | Lazertinib, LECLAZA | Sung Yong Lee, Yuhan Corporation | Non-small Cell Lung Cancer Stage III, EGFR Positive Non-small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer | 03/26 | 03/26 | | |
NCT04718649: Effectiveness and Safety of Celecoxib (Celebrex 200 mg) Combined With Joins in the Treatment of Degenerative Knee Osteoarthritis: a Randomized Controlled Trial |
|
|
| Not yet recruiting | N/A | 216 | RoW | Celebrex with Joins or not | The Catholic University of Korea, SK Chemicals Co., Ltd. | Osteoarthritis | 12/22 | 12/22 | | |
| Sung, Yong Gyu |
NCT04718649: Effectiveness and Safety of Celecoxib (Celebrex 200 mg) Combined With Joins in the Treatment of Degenerative Knee Osteoarthritis: a Randomized Controlled Trial |
|
|
| Not yet recruiting | N/A | 216 | RoW | Celebrex with Joins or not | The Catholic University of Korea, SK Chemicals Co., Ltd. | Osteoarthritis | 12/22 | 12/22 | | |
